Clostridium difficile infection is an important cause of intestinal disease, primarily affecting hospitalized patients exposed to antibiotics. Infection has been associated with prolonged hospital stays and excess healthcare expenditures. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat. Participants discuss one promising new treatment option, the development of human monoclonal antibodies that target either the bacterium itself or the toxin it produces.
Participants:
Sylvia Wong, Donnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, ON, Canada
David Humphreys, UCB Pharma, Slough, United Kingdom
by ccondayan